Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Sanofi (United States) | Researchclopedia

Back to institutions

Sanofi (United States)

Bridgewatercompany

7,407

Works

568,996

Citations

295

h-index

Top Research Topics

Asthma and respiratory diseases Dermatology and Skin Diseases Diabetes Management and Research

Top Researchers

Gregory Y.H. Lip Seoul National University

5,528 works307,008 citationsh-index: 212

Recent Research

Dupilumab Improves Prurigo Activity and Severity in Patients with Prurigo Nodularis: A Post Hoc Analysis of Pooled Results from the PRIME and PRIME2 Trials

Sonja Ständer,Claudia Zeidler,et al.

20260 citations

Lysosomal Storage Disorders Research

Diabetes Treatment and Management

Health Systems, Economic Evaluations, Quality of Life

Allergic Rhinitis and Sensitization

Influenza Virus Research Studies

Statistical Methods in Clinical Trials

Monoclonal and Polyclonal Antibodies Research

IL-33, ST2, and ILC Pathways

Eosinophilic Esophagitis

Jun Wang Zhejiang International Studies University

3,181 works295,088 citationsh-index: 222

Josef Coresh Boston Children's Hospital

1,893 works260,914 citationsh-index: 187

Deepak L. Bhatt Mount Sinai Hospital

3,650 works217,760 citationsh-index: 197

Maciej Banach John Paul II Catholic University of Lublin

1,563 works187,394 citationsh-index: 142

Elliott M. Antman Brigham and Women's Hospital

842 works184,430 citationsh-index: 169

Understanding Patient Preferences on Inflammatory Bowel Disease Treatment Modalities and Outcomes: A Global Targeted Literature Review

Isabelle Whittle,Eva Brown Hajdukova,et al.

20260 citations

Treatment of Haemophilia A Without Inhibitors: Real‐World Treatment Patterns and Clinical Outcomes in the US

Allison P. Wheeler,Lauren E. Amos,et al.

20260 citations

Analyses en sous-groupes dans l’étude de phase 3 HERCULES évaluant Tolebrutinib (TOL) chez des patients atteints de SEP-SP sans poussées

Edward Fox,Amit Bar-Or,et al.

20260 citations

Les lésions paramagnétiques (PRL) comme biomarqueurs pronostiques de l’accumulation du handicap dans les études de phase 3 évaluant tolébrutinib (TOL)

Jiwon Oh,R. H. Fox,et al.

20260 citations

Targeting of CD28 and CD38 as a potential novel therapeutic strategy for peripheral T-cell lymphomas

Aurélie Dupuy,Laura Pelletier,et al.

20260 citations